 |
LONG-TERM CARE
The majority of older women in nursing homes are likely to be deficient in vitamin D during winter months, and those with the lowest levels are at a significantly increased risk of death, according to a study published online February 8, in the Journal of Clinical Endocrinology & Metabolism. » More |
Editor's Pick
Teriflunomide: An orally administered disease-modifying drug for the treatment of multiple sclerosis
Teriflunomide is a once-daily, orally administered, disease-modifying drug undergoing FDA review as a potential therapy for patients with relapsing forms of multiple sclerosis (MS). If approved by FDA, teriflunomide would be one of the first available oral treatments for MS. » Click here. |
CONTINUING EDUCATION
Of the 35 new molecular entities approved by FDA in 2011, 17 are considered groundbreaking because of their potential to make a real difference in the lives of patients.
To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login. |
CLINICAL NEWS
Clinical pharmacists were instrumental in reducing errors in patients’ physician-acquired medication histories, according to a study published online on March 13 in the Annals of Pharmacotherapy. » More |
A new study of patients with moderate-to-severe Alzheimer’s disease found that extended treatment with donepezil could improve cognition and function for even severe patients; however, experts caution that the benefits of the drug were modest. » More |
Diacetylmorphine, or heroin, may be a more effective treatment than methadone for people with relapsing chronic opioid dependence, according to a study published in the Canadian Medical Association Journal. » More |
Ingenol mebutate topical gel (0.015% for face and scalp and 0.05% for trunk and extremities) was effective for treating actinic keratoses, a common precursor to sun-related, squamous cell carcinoma, according to a new study. » More |
FDA ACTIONS
FDA approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause. » More |
FDA has approved alendronate sodium (Binosto, EffRx Pharmaceuticals) effervescent tablets, the first effervescent osteoporosis treatment in a buffered solution. » More |
DRUG TRENDS
Amneal Pharmaceuticals has launched escitalopram oxalate oral solution in 5 mg/5 mL strength, the first generic of antianxiety/antidepressant Lexapro (Forest) in liquid form on the market. » More |
Survey
Yes
No
Respond here and see what your colleagues think too.
Want to see the results of our last survey regarding who performs medication therapy management in your health system? Click here. |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Formulary please take a moment to confirm your subscription by clicking here.
Thank you,
Formulary Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|